Monitoring changes in Pharmaceutical organisations: analysis of Business Models in the aspect of sustainable development

The relevance of the study of various types of business models of pharmaceutical companies and monitoring of ongoing changes is related to the high importance of the industry for ensuring technological sovereignty and increasing the competitiveness of Russia in the global economy. The Pharma 2030 strategy is aimed at sustainable development of the pharmaceutical industry, eliminating dependence on imports, creating sustainable pharmaceutical clusters of their own production of strategically important drugs, entering new export markets with advanced drugs. The purpose of the research is to substantiate the approach to monitoring changes and assessing various types of business models of pharmaceutical companies from the standpoint of their risk resistance during the transformation of the Russian economy. The study is based on such methods of analysis as assessment of development trends in the pharmaceutical industry, including state support, analysis of business models using the example of representative companies, identification of their competitive advantages, key risks and threats to sustainable development. The scientific findings of the study may be of practical interest to the Ministry of Industry and Trade of Russia, the Industrial Development Fund, and associations of pharmaceutical manufacturers, since it enables to evaluate successful functioning of the sectoral industry in accordance with the criteria of sustainable development (operational efficiency, innovation and investment activity, efficiency for key stakeholders) and assess prospects for the development of industry business models focused on sustainability criteria in this domain, as well as the need to adjust the strategy of the industry.